Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
10.1371/journal.pone.0232068
Saved in:
Main Authors: | Lim, S.-L., Xu, L., Han, B.-C., Shyamsunder, P., Chng, W.-J., Phillip Koeffler, H. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
Public Library of Science
2021
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/196135 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: Efficacy, biomarker and drug combinations
by: Lim, S.L., et al.
Published: (2021) -
THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
by: Shyamsunder, Pavithra, et al.
Published: (2022) -
Vγ9Vδ2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
by: Zhang, X, et al.
Published: (2022) -
QUANTITATIVE CHEMICAL PROTEOMICS INVESTIGATIONS OF TARGETS OF ANDROGRAPHOLIDE AND PROTEOLYSIS OF AUTOPHAGY
by: WANG JIGANG
Published: (2014) -
A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation
by: Chen, E.W., et al.
Published: (2021)